Vanguard Group Inc Castle Biosciences Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,748,752 shares of CSTL stock, worth $52.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,748,752
Previous 1,577,514
10.85%
Holding current value
$52.9 Million
Previous $34.3 Million
45.23%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$92.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$55.2 Million0.26% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$38.2 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$38 Million2.85% of portfolio
-
Dimensional Fund Advisors LP Austin, TX865KShares$26.2 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $795M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...